[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-001", "question": "A 58-year-old woman with hypertrophic cardiomyopathy presents with recurrent syncope despite maximum-dose beta-blocker therapy. Echocardiography reveals a resting left ventricular outflow tract (LVOT) gradient of 85 mmHg, systolic anterior motion of the mitral valve, and septal thickness of 22 mm. Coronary angiography shows a large first septal perforator arising from the left anterior descending artery supplying the basal septum. She is referred for alcohol septal ablation. During the procedure, after balloon occlusion of the septal perforator and injection of echocardiographic contrast, opacification is noted in the papillary muscle region in addition to the target septal area. What is the most appropriate next step?", "options": ["Proceed with alcohol injection as planned given adequate septal opacification", "Abort the procedure and refer for surgical myectomy", "Advance the balloon more distally and reassess contrast distribution", "Reduce the planned alcohol volume by 50% and proceed", "Switch to a different septal perforator branch if available"], "answer": "C", "answer_index": 2, "explanation": "Papillary muscle opacification during alcohol septal ablation indicates that alcohol injection would cause papillary muscle necrosis, potentially resulting in severe mitral regurgitation. The appropriate step is to reposition the balloon more distally to exclude the branch supplying the papillary muscle. Proceeding with injection (A) or reducing volume (D) risks catastrophic mitral regurgitation. Aborting immediately (B) is premature before attempting repositioning. Switching perforators (E) may be considered only if repositioning fails and another suitable branch exists.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question presents a classic intra-procedural complication during alcohol septal ablation: off-target contrast opacification of the papillary muscle. This is a critical safety check; proceeding with alcohol injection (Option A) or merely reducing volume (Option D) would likely cause papillary muscle necrosis and acute, catastrophic mitral regurgitation. The standard of care when off-target distribution is noted is to attempt to reposition the balloon to exclude the non-target territory while maintaining perfusion to the target basal septum. Advancing the balloon distally (Option C) is the most appropriate immediate technical maneuver to bypass the branch supplying the papillary muscle. Aborting for surgery (Option B) or switching vessels (Option E) are valid considerations only after attempts to safely cannulate the target vessel have failed. Therefore, Option C is the unique best answer, reflecting standard interventional cardiology protocols. The item is medically accurate, logically sound, and discriminates well between safe and unsafe procedural decisions.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question presents a classic intra-procedural complication during alcohol septal ablation: off-target contrast opacification of the papillary muscle. This is a critical safety check; proceeding with alcohol injection (Option A) or merely reducing volume (Option D) would likely cause papillary muscle necrosis and acute, catastrophic mitral regurgitation. The standard of care when off-target distribution is noted is to attempt to reposition the balloon to exclude the non-target territory while maintaining perfusion to the target basal septum. Advancing the balloon distally (Option C) is the most appropriate immediate technical maneuver to bypass the branch supplying the papillary muscle. Aborting for surgery (Option B) or switching vessels (Option E) are valid considerations only after attempts to safely cannulate the target vessel have failed. Therefore, Option C is the unique best answer, reflecting standard interventional cardiology protocols. The item is medically accurate, logically sound, and discriminates well between safe and unsafe procedural decisions.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-002", "question": "A 34-year-old man presents with progressive gait instability and cognitive decline over 18 months. Examination reveals vertical supranuclear gaze palsy, axial rigidity greater than limb rigidity, early postural instability with falls, and frontal release signs. Brain MRI shows midbrain atrophy with the 'hummingbird sign.' Genetic testing reveals a heterozygous mutation in the MAPT gene. His father died at age 45 with a similar presentation. Which tau isoform predominates in the neuropathological inclusions of this patient's condition?", "options": ["3-repeat tau (3R) exclusively", "4-repeat tau (4R) exclusively", "Mixed 3R and 4R tau in equal proportions", "Hyperphosphorylated tau without repeat domain specificity", "Truncated tau lacking the microtubule-binding domain"], "answer": "B", "answer_index": 1, "explanation": "This presentation describes progressive supranuclear palsy (PSP) phenotype associated with MAPT mutation. PSP is a 4-repeat (4R) tauopathy, with tau inclusions composed predominantly of 4R tau isoforms. Pick disease is characterized by 3R tau (A), while Alzheimer disease shows mixed 3R/4R tau (C). The tau in PSP is hyperphosphorylated but specifically 4R predominant, making (D) incomplete. Truncated tau (E) is not characteristic of PSP pathology.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with a classic Progressive Supranuclear Palsy (PSP) phenotype, evidenced by vertical supranuclear gaze palsy, early falls, axial rigidity, and the pathognomonic 'hummingbird sign' on MRI. The patient has a hereditary form (FTDP-17) due to a MAPT mutation. While MAPT mutations can theoretically lead to 3R, 4R, or mixed tau accumulation depending on the specific mutation, the genotype-phenotype correlation is strong: MAPT mutations presenting with a PSP-like syndrome (often affecting exon 10 splicing) are characterized by the accumulation of 4R tau isoforms. Sporadic PSP is also a classic 4R tauopathy. Therefore, the clinical and radiological evidence points uniquely to 4R tau pathology. Option A (3R) is characteristic of Pick disease. Option C (Mixed) is characteristic of Alzheimer disease or other FTDP-17 presentations (e.g., FTD-behavioral variant). The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with a classic Progressive Supranuclear Palsy (PSP) phenotype, evidenced by vertical supranuclear gaze palsy, early falls, axial rigidity, and the pathognomonic 'hummingbird sign' on MRI. The patient has a hereditary form (FTDP-17) due to a MAPT mutation. While MAPT mutations can theoretically lead to 3R, 4R, or mixed tau accumulation depending on the specific mutation, the genotype-phenotype correlation is strong: MAPT mutations presenting with a PSP-like syndrome (often affecting exon 10 splicing) are characterized by the accumulation of 4R tau isoforms. Sporadic PSP is also a classic 4R tauopathy. Therefore, the clinical and radiological evidence points uniquely to 4R tau pathology. Option A (3R) is characteristic of Pick disease. Option C (Mixed) is characteristic of Alzheimer disease or other FTDP-17 presentations (e.g., FTD-behavioral variant). The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-003", "question": "A 42-year-old woman with type 1 diabetes mellitus on insulin pump therapy presents with recurrent episodes of neuroglycopenia occurring 3-4 hours postprandially despite appropriate carbohydrate counting and bolus dosing. Continuous glucose monitoring shows rapid glucose drops from 180 mg/dL to 45 mg/dL within 90 minutes after meals. Gastric emptying study is normal. Anti-insulin antibodies are markedly elevated at 85% binding (normal <5%). Which mechanism best explains her hypoglycemic episodes?", "options": ["Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia", "Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action", "Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation", "Antibody-induced insulin resistance requiring higher doses with subsequent overdosing", "Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation"], "answer": "B", "answer_index": 1, "explanation": "Insulin autoimmune syndrome (IAS) or exogenous insulin antibody syndrome involves high-affinity anti-insulin antibodies that bind circulating insulin, creating a 'buffer' reservoir. This causes initial postprandial hyperglycemia (insulin bound and inactive), followed by delayed hypoglycemia when insulin dissociates from antibodies hours later. This explains the pattern of post-meal hyperglycemia followed by delayed severe hypoglycemia. Accelerated clearance (A) would cause persistent hyperglycemia. Receptor cross-reactivity (C) and alpha cell destruction (E) are not mechanisms of anti-insulin antibodies.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with Type 1 diabetes and markedly elevated anti-insulin antibodies (85% binding) presenting with recurrent hypoglycemia. This constellation is diagnostic of Exogenous Insulin Antibody Syndrome (EIAS). The pathophysiology involves antibodies binding to exogenous insulin (buffering), which prevents immediate absorption and action (often causing initial hyperglycemia), followed by the unpredictable dissociation of insulin from the antibodies hours later, resulting in hyperinsulinemia and hypoglycemia. Option B correctly describes this 'sponge' mechanism of buffering and delayed release. Option A is incorrect because antibodies typically prolong insulin half-life rather than accelerate clearance. Option C describes Type B insulin resistance (antibodies to the insulin receptor), which is a distinct entity. Option D describes a clinical consequence (resistance leading to high doses) but Option B provides the specific kinetic mechanism explaining the hypoglycemia. Note: The stem contains a temporal inconsistency; it describes episodes '3-4 hours postprandially' (consistent with the delayed release of EIAS) but the CGM data notes drops 'within 90 minutes after meals' (which is typically too early for this mechanism). However, given the definitive antibody findings and lack of options supporting early hypoglycemia (normal gastric emptying), Option B is the unique best answer.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with Type 1 diabetes and markedly elevated anti-insulin antibodies (85% binding) presenting with recurrent hypoglycemia. This constellation is diagnostic of Exogenous Insulin Antibody Syndrome (EIAS). The pathophysiology involves antibodies binding to exogenous insulin (buffering), which prevents immediate absorption and action (often causing initial hyperglycemia), followed by the unpredictable dissociation of insulin from the antibodies hours later, resulting in hyperinsulinemia and hypoglycemia. Option B correctly describes this 'sponge' mechanism of buffering and delayed release. Option A is incorrect because antibodies typically prolong insulin half-life rather than accelerate clearance. Option C describes Type B insulin resistance (antibodies to the insulin receptor), which is a distinct entity. Option D describes a clinical consequence (resistance leading to high doses) but Option B provides the specific kinetic mechanism explaining the hypoglycemia. Note: The stem contains a temporal inconsistency; it describes episodes '3-4 hours postprandially' (consistent with the delayed release of EIAS) but the CGM data notes drops 'within 90 minutes after meals' (which is typically too early for this mechanism). However, given the definitive antibody findings and lack of options supporting early hypoglycemia (normal gastric emptying), Option B is the unique best answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-004", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy-defibrillator (CRT-D) presents for device interrogation. He reports improved functional capacity since implantation 6 months ago. Interrogation reveals 94% biventricular pacing. However, the device electrograms show that during intrinsic AV conduction, the LV lead captures occurs 40 ms after RV lead capture, and during biventricular pacing, LV capture occurs 15 ms before RV capture. His current AV delay is programmed at 120 ms sensed/150 ms paced. What programming change would most likely optimize his cardiac resynchronization?", "options": ["Shorten the AV delay to 80 ms sensed/110 ms paced", "Lengthen the AV delay to 180 ms sensed/210 ms paced", "Program VV delay with RV preceding LV by 40 ms", "Program VV delay with LV preceding RV by 30 ms", "Enable automatic AV and VV optimization algorithm"], "answer": "A", "answer_index": 0, "explanation": "The electrogram findings indicate that intrinsic conduction results in significant LV delay (LV activates 40 ms after RV), consistent with left bundle branch block pattern. During BiV pacing, LV leads RV by only 15 ms, suggesting suboptimal resynchronization. The key issue is that with a 120 ms AV delay, there may be fusion with intrinsic conduction compromising true biventricular capture. Shortening the AV delay ensures complete ventricular capture by the device before intrinsic conduction, maximizing resynchronization benefit. Programming RV to precede LV (C) would worsen the native LBBB pattern. Lengthening AV delay (B) would increase fusion. While automatic algorithms (E) exist, the specific findings here indicate the need for shorter AV delay.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is medically inaccurate and logically underspecified. First, the stem contains a major terminology error: it states that during 'intrinsic AV conduction,' the LV lead 'captures.' In reality, the device would 'sense' intrinsic activation; 'capture' implies pacing, which contradicts the presence of intrinsic conduction. Second, the item is underspecified regarding the choice between Option A (AV delay) and Option D (VV timing). To determine if the current 120 ms sensed AV delay is causing fusion (justifying Option A), the intrinsic PR interval is required. Without knowing the PR interval, one cannot confirm that 120 ms is too long. Third, the rationale is internally inconsistent: it notes that the current VV timing (15 ms) suggests 'suboptimal resynchronization' (which implies Option D is the fix) but then pivots to selecting Option A based on assumed fusion. Finally, the patient is a clinical responder with improved capacity, making the urgency to change settings debatable. A unique best answer cannot be derived without the intrinsic PR interval and clarification of the terminology.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is medically inaccurate and logically underspecified. First, the stem contains a major terminology error: it states that during 'intrinsic AV conduction,' the LV lead 'captures.' In reality, the device would 'sense' intrinsic activation; 'capture' implies pacing, which contradicts the presence of intrinsic conduction. Second, the item is underspecified regarding the choice between Option A (AV delay) and Option D (VV timing). To determine if the current 120 ms sensed AV delay is causing fusion (justifying Option A), the intrinsic PR interval is required. Without knowing the PR interval, one cannot confirm that 120 ms is too long. Third, the rationale is internally inconsistent: it notes that the current VV timing (15 ms) suggests 'suboptimal resynchronization' (which implies Option D is the fix) but then pivots to selecting Option A based on assumed fusion. Finally, the patient is a clinical responder with improved capacity, making the urgency to change settings debatable. A unique best answer cannot be derived without the intrinsic PR interval and clarification of the terminology.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-005", "question": "A 29-year-old woman presents with acute onset of right-sided weakness and aphasia. CT head is negative for hemorrhage. CT angiography reveals complete occlusion of the left middle cerebral artery M1 segment. CT perfusion shows a small core infarct (8 mL) with large penumbra (95 mL mismatch). Her NIHSS is 18. Time last known well is 2 hours ago. She has a history of antiphospholipid syndrome with prior deep vein thrombosis, currently on warfarin with INR of 3.2. What is the most appropriate acute intervention?", "options": ["Intravenous alteplase followed by mechanical thrombectomy", "Mechanical thrombectomy alone without intravenous thrombolysis", "Intravenous alteplase alone with close monitoring", "Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy", "Anticoagulation reversal with idarucizumab followed by mechanical thrombectomy"], "answer": "B", "answer_index": 1, "explanation": "This patient has a large vessel occlusion with favorable perfusion imaging (small core, large penumbra) within the thrombectomy window. However, her INR of 3.2 is a contraindication to IV alteplase (INR >1.7 is exclusion criterion). Mechanical thrombectomy is not contraindicated by anticoagulation status and should be performed emergently. IV alteplase (A, C) is contraindicated with therapeutic anticoagulation. PCC reversal followed by alteplase (D) delays definitive treatment and alteplase remains relatively contraindicated even after reversal. Idarucizumab (E) reverses dabigatran, not warfarin.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict on keyed answer: Correct best. The vignette presents a clear case of acute ischemic stroke due to a large vessel occlusion (Left M1 MCA) within the early time window (2 hours). The critical discriminating factor is the patient's INR of 3.2 due to warfarin use. According to AHA/ASA guidelines, intravenous alteplase (IVT) is contraindicated in patients with an INR > 1.7. Consequently, options involving IVT (A, C) are incorrect. Option D (reversal to give IVT) is incorrect because delaying definitive mechanical thrombectomy (MT) to reverse anticoagulation for the sake of IVT is not standard of care and delays reperfusion. Option E is incorrect because idarucizumab reverses dabigatran, not warfarin. Option B is the correct best answer: the patient meets all criteria for mechanical thrombectomy (LVO, favorable perfusion mismatch, time window), and therapeutic anticoagulation is not a contraindication for endovascular intervention. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict on keyed answer: Correct best. The vignette presents a clear case of acute ischemic stroke due to a large vessel occlusion (Left M1 MCA) within the early time window (2 hours). The critical discriminating factor is the patient's INR of 3.2 due to warfarin use. According to AHA/ASA guidelines, intravenous alteplase (IVT) is contraindicated in patients with an INR > 1.7. Consequently, options involving IVT (A, C) are incorrect. Option D (reversal to give IVT) is incorrect because delaying definitive mechanical thrombectomy (MT) to reverse anticoagulation for the sake of IVT is not standard of care and delays reperfusion. Option E is incorrect because idarucizumab reverses dabigatran, not warfarin. Option B is the correct best answer: the patient meets all criteria for mechanical thrombectomy (LVO, favorable perfusion mismatch, time window), and therapeutic anticoagulation is not a contraindication for endovascular intervention. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-006", "question": "A 55-year-old man with severe persistent asthma on high-dose inhaled corticosteroids, long-acting beta-agonist, long-acting muscarinic antagonist, and monthly omalizumab presents with continued poor control. Spirometry shows FEV1 45% predicted with 15% bronchodilator response. Laboratory studies reveal blood eosinophils 450 cells/μL, total IgE 850 IU/mL, and FeNO 55 ppb. Sputum analysis shows 8% eosinophils. Despite confirmed adherence and proper inhaler technique, he has had 4 exacerbations requiring systemic corticosteroids in the past year. Which biologic switch would most likely provide additional benefit?", "options": ["Dupilumab targeting IL-4 receptor alpha", "Benralizumab targeting IL-5 receptor alpha", "Mepolizumab targeting IL-5", "Tezepelumab targeting thymic stromal lymphopoietin", "Continue omalizumab with addition of low-dose oral corticosteroids"], "answer": "D", "answer_index": 3, "explanation": "This patient has severe eosinophilic asthma failing omalizumab (anti-IgE) therapy despite elevated biomarkers (eosinophils, FeNO). Tezepelumab targets TSLP, an epithelial cytokine upstream of multiple inflammatory pathways (Th2, ILC2), and has demonstrated efficacy regardless of baseline eosinophil count or IgE levels, including in patients who failed other biologics. While anti-IL-5/IL-5R agents (B, C) and dupilumab (A) target eosinophilic inflammation, tezepelumab's upstream mechanism may provide benefit when anti-IgE therapy has failed despite persistent type 2 inflammation. Adding oral corticosteroids (E) increases adverse effects without addressing the underlying inflammatory pathway.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible). The vignette describes a patient with severe uncontrolled asthma failing omalizumab (anti-IgE) despite a clear Type 2 inflammatory profile (Eosinophils 450, FeNO 55, IgE 850). Current guidelines (e.g., GINA, ERS/ATS) recommend switching to a different class of biologic if the initial one fails. Given the patient's biomarkers, switching to Dupilumab (Option A, anti-IL-4Rα), Benralizumab/Mepolizumab (Options B/C, anti-IL-5 pathway), or Tezepelumab (Option D, anti-TSLP) are all appropriate, evidence-based steps. There is no head-to-head data or consensus establishing Tezepelumab as definitively superior to Dupilumab or Benralizumab for this specific T2-high phenotype. In fact, the elevated FeNO (55 ppb) is a strong predictor of response to Dupilumab. While Tezepelumab is a valid option, it cannot be singled out as the unique best answer over Dupilumab or Benralizumab without additional constraints (e.g., comorbidities or specific contraindications).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible). The vignette describes a patient with severe uncontrolled asthma failing omalizumab (anti-IgE) despite a clear Type 2 inflammatory profile (Eosinophils 450, FeNO 55, IgE 850). Current guidelines (e.g., GINA, ERS/ATS) recommend switching to a different class of biologic if the initial one fails. Given the patient's biomarkers, switching to Dupilumab (Option A, anti-IL-4Rα), Benralizumab/Mepolizumab (Options B/C, anti-IL-5 pathway), or Tezepelumab (Option D, anti-TSLP) are all appropriate, evidence-based steps. There is no head-to-head data or consensus establishing Tezepelumab as definitively superior to Dupilumab or Benralizumab for this specific T2-high phenotype. In fact, the elevated FeNO (55 ppb) is a strong predictor of response to Dupilumab. While Tezepelumab is a valid option, it cannot be singled out as the unique best answer over Dupilumab or Benralizumab without additional constraints (e.g., comorbidities or specific contraindications).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-007", "question": "A 48-year-old woman is brought to the emergency department after being found unresponsive at home. She has a history of depression. On examination, she is comatose with pinpoint pupils, respiratory rate of 6/min, temperature 35.8°C, and blood pressure 90/60 mmHg. ECG shows QRS duration of 145 ms with a terminal R wave in aVR of 4 mm. After securing the airway and administering naloxone without response, what is the most appropriate next intervention?", "options": ["Intravenous flumazenil 0.2 mg", "Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55", "Intravenous lipid emulsion 20% bolus", "Intravenous glucagon 5 mg bolus", "Emergent hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation (coma, miosis, respiratory depression, hypotension) with ECG findings of QRS widening >100 ms and terminal R wave in aVR >3 mm is classic for tricyclic antidepressant (TCA) toxicity. The sodium channel blockade causing cardiac toxicity is treated with sodium bicarbonate, which increases extracellular sodium (overcoming channel blockade) and alkalinizes serum (increasing protein binding of TCA). Target pH is 7.50-7.55. Flumazenil (A) is contraindicated as it may precipitate seizures in TCA overdose. Lipid emulsion (C) is second-line. Glucagon (D) is for beta-blocker toxicity. Hemodialysis (E) is ineffective for TCAs due to high protein binding and large volume of distribution.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with coma, hypotension, and ECG findings pathognomonic for Tricyclic Antidepressant (TCA) toxicity (QRS duration >100 ms and a prominent terminal R wave in aVR). Although pinpoint pupils are classically associated with opioid toxicity (or pontine pathology) and TCAs typically cause mydriasis due to anticholinergic effects, the specific ECG abnormalities indicate severe sodium channel blockade, which is an immediate life threat. The lack of response to naloxone suggests opioids are not the primary driver of the current state or that a co-ingestion is present. Regardless of the pupillary findings, the ECG mandates immediate treatment with sodium bicarbonate (Choice B) to narrow the QRS and prevent ventricular arrhythmias. Flumazenil is contraindicated in suspected TCA overdose due to seizure risk. The item is logically valid as the ECG findings provide a definitive indication for the keyed intervention, overriding the atypical pupillary exam.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with coma, hypotension, and ECG findings pathognomonic for Tricyclic Antidepressant (TCA) toxicity (QRS duration >100 ms and a prominent terminal R wave in aVR). Although pinpoint pupils are classically associated with opioid toxicity (or pontine pathology) and TCAs typically cause mydriasis due to anticholinergic effects, the specific ECG abnormalities indicate severe sodium channel blockade, which is an immediate life threat. The lack of response to naloxone suggests opioids are not the primary driver of the current state or that a co-ingestion is present. Regardless of the pupillary findings, the ECG mandates immediate treatment with sodium bicarbonate (Choice B) to narrow the QRS and prevent ventricular arrhythmias. Flumazenil is contraindicated in suspected TCA overdose due to seizure risk. The item is logically valid as the ECG findings provide a definitive indication for the keyed intervention, overriding the atypical pupillary exam.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-008", "question": "A 62-year-old man with longstanding type 2 diabetes presents with a 6-month history of burning pain and numbness in his feet, now extending to mid-calf. Examination reveals absent ankle reflexes, reduced pinprick and vibration sense to the knees bilaterally, and mild weakness of toe extension. Nerve conduction studies show absent sural sensory responses, reduced peroneal motor amplitudes with mildly slowed conduction velocities, and prolonged F-wave latencies. Hemoglobin A1c is 7.2%. He is started on duloxetine with minimal improvement after 8 weeks. Gabapentin is added and titrated to 1800 mg daily with partial response. Which additional intervention has the strongest evidence for further symptomatic improvement?", "options": ["Alpha-lipoic acid 600 mg IV daily for 3 weeks", "Topical capsaicin 8% patch application to affected areas", "Spinal cord stimulation trial", "Transcutaneous electrical nerve stimulation (TENS)", "Acupuncture twice weekly for 12 weeks"], "answer": "C", "answer_index": 2, "explanation": "This patient has painful diabetic peripheral neuropathy refractory to first-line (duloxetine) and second-line (gabapentin) pharmacotherapy. Spinal cord stimulation (SCS) has Level 1 evidence from randomized controlled trials (SENZA-PDN, others) demonstrating significant pain reduction in refractory painful diabetic neuropathy, with FDA approval for this indication. Alpha-lipoic acid (A) has modest evidence primarily from European studies. High-concentration capsaicin (B) provides temporary relief but evidence in diabetic neuropathy is limited. TENS (D) and acupuncture (E) have weaker evidence compared to SCS for refractory cases.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with painful diabetic peripheral neuropathy (DPN) who has had an inadequate response to first-line (SNRI) and second-line (gabapentinoid) agents. The question asks for the intervention with the strongest evidence for further improvement among the choices. Option C (Spinal cord stimulation, specifically 10-kHz high-frequency SCS) is the best answer. The landmark SENZA-PDN randomized controlled trial (2021) provided Level 1 evidence for substantial pain relief in patients with DPN refractory to conventional medical management, leading to FDA approval for this indication. While Option B (Capsaicin 8% patch) is also FDA-approved and effective, the effect sizes and evidence strength for SCS in refractory cases are currently viewed as superior in the pain literature. Option A (IV Alpha-lipoic acid) has evidence but is logistically burdensome (daily IVs) and not standard of care in the US. Options D (TENS) and E (Acupuncture) have inconsistent or lower-quality evidence compared to SCS. The item accurately reflects recent updates in pain management guidelines.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with painful diabetic peripheral neuropathy (DPN) who has had an inadequate response to first-line (SNRI) and second-line (gabapentinoid) agents. The question asks for the intervention with the strongest evidence for further improvement among the choices. Option C (Spinal cord stimulation, specifically 10-kHz high-frequency SCS) is the best answer. The landmark SENZA-PDN randomized controlled trial (2021) provided Level 1 evidence for substantial pain relief in patients with DPN refractory to conventional medical management, leading to FDA approval for this indication. While Option B (Capsaicin 8% patch) is also FDA-approved and effective, the effect sizes and evidence strength for SCS in refractory cases are currently viewed as superior in the pain literature. Option A (IV Alpha-lipoic acid) has evidence but is logistically burdensome (daily IVs) and not standard of care in the US. Options D (TENS) and E (Acupuncture) have inconsistent or lower-quality evidence compared to SCS. The item accurately reflects recent updates in pain management guidelines.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-009", "question": "A 71-year-old man with COPD GOLD stage III is hospitalized for acute exacerbation. On day 3, despite antibiotics, systemic corticosteroids, and scheduled bronchodilators, he remains dyspneic with respiratory rate 28/min, accessory muscle use, and ABG showing pH 7.31, PaCO2 58 mmHg, PaO2 55 mmHg on 4L nasal cannula. He is alert and cooperative. Bilevel positive airway pressure (BiPAP) is initiated at IPAP 12/EPAP 5 cm H2O. After 2 hours, repeat ABG shows pH 7.29, PaCO2 62 mmHg. He remains tachypneic but is tolerating the mask. What is the most appropriate next step?", "options": ["Increase IPAP to 18 cm H2O and reassess in 1-2 hours", "Proceed with endotracheal intubation and mechanical ventilation", "Add heliox (helium-oxygen mixture) to the BiPAP circuit", "Switch to high-flow nasal cannula at 60 L/min", "Increase EPAP to 10 cm H2O while maintaining IPAP"], "answer": "A", "answer_index": 0, "explanation": "The patient has acute hypercapnic respiratory failure from COPD exacerbation with initial NIV settings that are inadequate (worsening hypercapnia). The driving pressure (IPAP-EPAP = 7 cm H2O) is insufficient for adequate ventilation. Increasing IPAP to 18 cm H2O (driving pressure 13 cm H2O) will augment tidal volume and improve CO2 clearance. Intubation (B) is premature as he is tolerating NIV and is not deteriorating clinically. Heliox (C) reduces airway resistance but doesn't address ventilation. HFNC (D) provides less ventilatory support than BiPAP for hypercapnic failure. Increasing EPAP alone (E) would reduce driving pressure further, worsening ventilation.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question presents a classic management dilemma for acute hypercapnic respiratory failure in COPD: distinguishing between NIV failure requiring intubation and inadequate NIV settings requiring adjustment. The patient is worsening (pH dropped from 7.31 to 7.29) after 2 hours, which is a poor prognostic sign. However, the stem explicitly notes the patient is 'alert and cooperative' and 'tolerating the mask,' and the initial settings (IPAP 12 / EPAP 5) yield a driving pressure (pressure support) of only 7 cm H2O. In acute exacerbations, a driving pressure of 7 is often insufficient to unload respiratory muscles or augment tidal volume significantly. Therefore, the failure to improve is likely due to inadequate support rather than refractory physiology. Increasing IPAP (Option A) increases the driving pressure to 13 cm H2O, addressing the ventilation deficit. Intubation (Option B) is incorrect because the patient protects his airway, is cooperative, and has not yet received a trial of adequate NIV support. Option E would reduce driving pressure, worsening the acidosis. The item is logically sound, medically accurate, and reinforces a specific, high-yield clinical concept.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question presents a classic management dilemma for acute hypercapnic respiratory failure in COPD: distinguishing between NIV failure requiring intubation and inadequate NIV settings requiring adjustment. The patient is worsening (pH dropped from 7.31 to 7.29) after 2 hours, which is a poor prognostic sign. However, the stem explicitly notes the patient is 'alert and cooperative' and 'tolerating the mask,' and the initial settings (IPAP 12 / EPAP 5) yield a driving pressure (pressure support) of only 7 cm H2O. In acute exacerbations, a driving pressure of 7 is often insufficient to unload respiratory muscles or augment tidal volume significantly. Therefore, the failure to improve is likely due to inadequate support rather than refractory physiology. Increasing IPAP (Option A) increases the driving pressure to 13 cm H2O, addressing the ventilation deficit. Intubation (Option B) is incorrect because the patient protects his airway, is cooperative, and has not yet received a trial of adequate NIV support. Option E would reduce driving pressure, worsening the acidosis. The item is logically sound, medically accurate, and reinforces a specific, high-yield clinical concept.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-010", "question": "A 38-year-old woman presents with palpitations and near-syncope. ECG shows a regular wide complex tachycardia at 220 bpm with RBBB morphology, northwest axis, and AV dissociation. She is hemodynamically stable with blood pressure 105/70 mmHg. Adenosine 12 mg IV is administered without effect. Procainamide infusion is started, and after 8 minutes (750 mg administered), the rhythm converts to sinus. Post-conversion ECG reveals sinus rhythm with a short PR interval (100 ms), delta waves, and QRS duration of 140 ms with positive delta wave in V1. Which electrophysiologic finding would most strongly support proceeding with catheter ablation rather than medical management?", "options": ["Accessory pathway effective refractory period of 270 ms", "Inducible orthodromic atrioventricular reentrant tachycardia", "Accessory pathway located in the left lateral position", "Shortest pre-excited RR interval during induced atrial fibrillation of 220 ms", "Decremental conduction properties of the accessory pathway"], "answer": "D", "answer_index": 3, "explanation": "This patient has Wolff-Parkinson-White syndrome with documented antidromic AVRT (wide complex tachycardia with AV dissociation, RBBB morphology suggesting left-sided pathway). The most important risk stratification parameter is the shortest pre-excited RR interval (SPERRI) during atrial fibrillation, which reflects the accessory pathway's ability to conduct rapid atrial rates to the ventricle. SPERRI ≤250 ms indicates high-risk pathway capable of conducting AF at rates that could degenerate to ventricular fibrillation, strongly favoring ablation. Accessory pathway ERP (A) is less predictive than SPERRI. Inducible orthodromic AVRT (B) and pathway location (C) don't indicate sudden death risk. Decremental properties (E) actually suggest lower risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item contains a fundamental medical contradiction. The stem describes a wide complex tachycardia with 'AV dissociation,' which is the hallmark of Ventricular Tachycardia (VT) and physiologically excludes Atrioventricular Reentrant Tachycardia (AVRT). In AVRT (orthodromic or antidromic), the atria and ventricles are obligate parts of the macroreentrant circuit, requiring 1:1 AV association. The provided explanation incorrectly asserts that this presentation represents antidromic AVRT. Despite this incoherence, the intended key (D) is identifiable based on standard WPW risk stratification: a Shortest Pre-Excited RR Interval (SPERRI) ≤250 ms during atrial fibrillation is a validated marker for high risk of sudden cardiac death (via degeneration to VF), which is the strongest indication for ablation. Option A (ERP 270 ms) suggests lower risk. While the key is correct in isolation regarding WPW risk, the stem's description of the tachycardia mechanism is physiologically impossible, rendering the vignette internally inconsistent.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item contains a fundamental medical contradiction. The stem describes a wide complex tachycardia with 'AV dissociation,' which is the hallmark of Ventricular Tachycardia (VT) and physiologically excludes Atrioventricular Reentrant Tachycardia (AVRT). In AVRT (orthodromic or antidromic), the atria and ventricles are obligate parts of the macroreentrant circuit, requiring 1:1 AV association. The provided explanation incorrectly asserts that this presentation represents antidromic AVRT. Despite this incoherence, the intended key (D) is identifiable based on standard WPW risk stratification: a Shortest Pre-Excited RR Interval (SPERRI) ≤250 ms during atrial fibrillation is a validated marker for high risk of sudden cardiac death (via degeneration to VF), which is the strongest indication for ablation. Option A (ERP 270 ms) suggests lower risk. While the key is correct in isolation regarding WPW risk, the stem's description of the tachycardia mechanism is physiologically impossible, rendering the vignette internally inconsistent.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}]